BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 16979445)

  • 1. Systemic targeted radionuclide therapy: potential new areas.
    Wong JY
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S74-82. PubMed ID: 16979445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basic immunology of antibody targeted radiotherapy.
    Wong JY
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S8-14. PubMed ID: 16979446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promise of targeted {alpha}-particle therapy.
    Mulford DA; Scheinberg DA; Jurcic JG
    J Nucl Med; 2005 Jan; 46 Suppl 1():199S-204S. PubMed ID: 15653670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends.
    Steiner M; Neri D
    Clin Cancer Res; 2011 Oct; 17(20):6406-16. PubMed ID: 22003068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-based targeted radiation to pediatric tumors.
    Modak S; Cheung NK
    J Nucl Med; 2005 Jan; 46 Suppl 1():157S-63S. PubMed ID: 15653664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens.
    Reilly RM
    J Nucl Med; 2006 Feb; 47(2):196-9. PubMed ID: 16455623
    [No Abstract]   [Full Text] [Related]  

  • 8. Principles of radioimmunotherapy for hematologists and oncologists.
    Press OW; Rasey J
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Technological advances in radioimmunotherapy.
    Dearling JL; Pedley RB
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):457-69. PubMed ID: 17537620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
    Sharkey RM; Goldenberg DM
    J Nucl Med; 2005 Jan; 46 Suppl 1():115S-27S. PubMed ID: 15653660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose painting and theragnostic imaging: towards the prescription, planning and delivery of biologically targeted dose distributions in external beam radiation oncology.
    Bentzen SM
    Cancer Treat Res; 2008; 139():41-62. PubMed ID: 18236711
    [No Abstract]   [Full Text] [Related]  

  • 12. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isobologram analysis of triple therapies.
    Niyazi M; Belka C
    Radiat Oncol; 2006 Oct; 1():39. PubMed ID: 17044920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of dosimetry for Systemic Targeted Radionuclide Therapy (STaRT).
    Wessels BW; Syh JH; Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S39-45. PubMed ID: 16979438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-guided radiation therapy of cancer.
    Koppe MJ; Postema EJ; Aarts F; Oyen WJ; Bleichrodt RP; Boerman OC
    Cancer Metastasis Rev; 2005 Dec; 24(4):539-67. PubMed ID: 16408161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of therapy of solid tumors.
    Jhanwar YS; Divgi C
    J Nucl Med; 2005 Jan; 46 Suppl 1():141S-50S. PubMed ID: 15653662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy of prostate cancer.
    Smith-Jones PM
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):297-304. PubMed ID: 15640793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining systemic bisphosphonates with palliative external beam radiotherapy or bone-targeted radionuclide therapy: interactions and effectiveness.
    Vassiliou V; Bruland O; Janjan N; Lutz S; Kardamakis D; Hoskin P
    Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):665-7. PubMed ID: 19700270
    [No Abstract]   [Full Text] [Related]  

  • 19. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
    Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
    Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides.
    Rao DV; Howell RW
    J Nucl Med; 1993 Oct; 34(10):1801-10. PubMed ID: 8410301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.